参松养心胶囊与比索洛尔治疗脑心综合征心律失常的疗效比较

目的比较参松养心胶囊与比索洛尔治疗脑心综合征心律失常的临床疗效。方法选择哈励逊国际和平医院2013年3月—2017年5月脑心综合征心律失常患者92例,随机分为对照组和治疗组,每组各46例。对照组在常规治疗的基础上口服富马酸比索洛尔片,2.5 mg/次,1次/d。治疗组在常规治疗的基础上口服参松养心胶囊,1.2 g/次,3次/d。两组患者均连续治疗4周。观察两组的临床疗效,同时比较治疗前后两组的心电图疗效、儿茶酚胺、血清丙二醛(MDA)、超氧化物歧化酶(SOD)水平变化和不良反应情况。结果治疗后,对照组患者的总有效率为78.26%,显著低于治疗组的93.48%,两组比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组患者心电图疗效分别为56.52%、76.09%,两组比较差异具有统计学意义(P0.05)。治疗后,两组去甲肾上腺素(NE)、肾上腺素(E)和多巴胺(DA)水平较治疗前均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组儿茶酚胺水平均明显低于对照组,两组比较差异具有统计学意义(P0.05)。两组血清MDA水平降低,SOD水平升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组MDA和SOD水平显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗组的不良反应发生率(6.52%)显著低于对照组(21.73%),两组比较差异具有统计学意义。结论与比索洛尔相比,参松养心胶囊治疗脑心综合征心律失常的效果更优,安全性更高,具有一定的临床应用价值。

Comparison on clinical efficacy between Shensong Yangxin Capsules and bisoprolol in treatment of cerebrocardiac syndrome with arrhythmia

Objective To compare the clinical effect between Shensong Yangxin Capsules and bisoprolol in treatment of cerebrocardiac syndrome with arrhythmia. Methods Patients (92 cases) with cerebrocardiac syndrome with arrhythmia in Harrison International Peace Hospital from March 2013 to May 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Bisoprolol Fumarate Tablets on the basis of conventional therapy, 2.5 mg/time, once daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of conventional therapy, 1.2 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the ECG curative effect, catecholamine, malondialdehyde (MDA), superoxide dismutase (SOD) levels in serum, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 78.26%, which was significantly lower than 93.48% in the treatment group, and the difference was statistically significant between two groups (P<0.05). After treatment, the ECG curative effect in the control and treatment groups were 56.52% and 76.09%, respectively, and there were differences between two groups (P<0.05). After treatment, NE, E, and DA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the catecholamine level in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). MDA level in serum was decreased, but SOD level was increased, and the difference was statistically significant in the same group (P<0.05). And the MDA and SOD levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). The rate of adverse reactions in the treatment group was 6.52%, which was significantly lower than 21.73% in the control group, and the difference was statistically significant between two groups (P<0.05). Conclusion Compared with bisoprolol, Shensong Yangxin Capsules has better clinical effect in treatment of cerebrocardiac syndrome with arrhythmia with high safety, which has a certain clinical application value.